DYN supply chain intelligence for Dyne Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VENDOR | VENDOR | 90% | Pursuant to an agreement with a vendor providing contract research and manufacturing services, the vendor has provided the Company with extended payment terms with respect to a portion of the service… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported … |
| CELG-RI | CELG-RI | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| MAZE | Maze Therapeutics, Inc. | 72% | Reciprocal relationship from MAZE graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| MAZE | Maze Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph:… |
| MRK | Merck & Co., Inc. | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| RNAM | RNAM | 72% | that the FORCE platform achieved delivery to the CNS. Intravenous, or IV, administration of FORCE conjugate, our proprietary Fab antibody conjugated to an ASO, achieved delivery to the CNS via TfR1 i… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN graph: that the FORCE platform achieved delivery to the CNS. Intravenous, or IV, administration of FORCE conjugate, our propr… |
| SRRK | Scholar Rock Holding Corporation | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| SRRK | Scholar Rock Holding Corporation | 72% | Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| TRDA | Entrada Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage an… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant… |
| WVE | Wave Life Sciences Ltd. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ARWR gra… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: pagation, compounding, or proce… |
| CELG-RI | CELG-RI | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from DYN graph: Reciprocal relationship from IONS graph: Reciprocal relationship from DYN graph: Reciprocal relationship from IONS gra… |
| MAZE | Maze Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| MAZE | Maze Therapeutics, Inc. | 72% | Reciprocal relationship from MAZE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| MRK | Merck & Co., Inc. | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or o… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| RNAM | RNAM | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRPT gra… |
| SRRK | Scholar Rock Holding Corporation | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| SRRK | Scholar Rock Holding Corporation | 72% | Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| TRDA | Entrada Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from DYN graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late delive… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph:… |
| WVE | Wave Life Sciences Ltd. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DYN-DEBT | Debt stack $168.7M | 90% | Market cache reports total debt of $168.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DYN-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME | T. Rowe Price Investment Management, Inc. | 90% | 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 232 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| ALT | Altimmune, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 1 | ['receiving'] |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| SVRA | Savara Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| CVSI | CV Sciences, Inc. | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 2 |